nodes	percent_of_prediction	percent_of_DWPC	metapath
Topiramate—Back pain—Vincristine—lymphatic system cancer	0.00095	0.00095	CcSEcCtD
Topiramate—Vomiting—Teniposide—lymphatic system cancer	0.000949	0.000949	CcSEcCtD
Topiramate—Agitation—Carmustine—lymphatic system cancer	0.000946	0.000946	CcSEcCtD
Topiramate—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000942	0.000942	CcSEcCtD
Topiramate—Asthenia—Fludarabine—lymphatic system cancer	0.000942	0.000942	CcSEcCtD
Topiramate—Rash—Teniposide—lymphatic system cancer	0.000942	0.000942	CcSEcCtD
Topiramate—Dermatitis—Teniposide—lymphatic system cancer	0.000941	0.000941	CcSEcCtD
Topiramate—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000937	0.000937	CcSEcCtD
Topiramate—Headache—Teniposide—lymphatic system cancer	0.000935	0.000935	CcSEcCtD
Topiramate—Pruritus—Fludarabine—lymphatic system cancer	0.000929	0.000929	CcSEcCtD
Topiramate—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.000928	0.000928	CcSEcCtD
Topiramate—Back pain—Mitoxantrone—lymphatic system cancer	0.000926	0.000926	CcSEcCtD
Topiramate—Leukopenia—Carmustine—lymphatic system cancer	0.000921	0.000921	CcSEcCtD
Topiramate—Anorexia—Bleomycin—lymphatic system cancer	0.000917	0.000917	CcSEcCtD
Topiramate—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.00091	0.00091	CcSEcCtD
Topiramate—Anaemia—Vincristine—lymphatic system cancer	0.000908	0.000908	CcSEcCtD
Topiramate—Agitation—Vincristine—lymphatic system cancer	0.000903	0.000903	CcSEcCtD
Topiramate—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000902	0.000902	CcSEcCtD
Topiramate—Polyuria—Methotrexate—lymphatic system cancer	0.000901	0.000901	CcSEcCtD
Topiramate—Hypotension—Bleomycin—lymphatic system cancer	0.000899	0.000899	CcSEcCtD
Topiramate—Diarrhoea—Fludarabine—lymphatic system cancer	0.000898	0.000898	CcSEcCtD
Topiramate—Convulsion—Carmustine—lymphatic system cancer	0.000892	0.000892	CcSEcCtD
Topiramate—Hypertension—Carmustine—lymphatic system cancer	0.000889	0.000889	CcSEcCtD
Topiramate—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000888	0.000888	CcSEcCtD
Topiramate—Nausea—Teniposide—lymphatic system cancer	0.000887	0.000887	CcSEcCtD
Topiramate—Anaemia—Mitoxantrone—lymphatic system cancer	0.000884	0.000884	CcSEcCtD
Topiramate—Vertigo—Vincristine—lymphatic system cancer	0.000883	0.000883	CcSEcCtD
Topiramate—Hepatic failure—Methotrexate—lymphatic system cancer	0.000881	0.000881	CcSEcCtD
Topiramate—Leukopenia—Vincristine—lymphatic system cancer	0.000879	0.000879	CcSEcCtD
Topiramate—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000877	0.000877	CcSEcCtD
Topiramate—Chest pain—Carmustine—lymphatic system cancer	0.000876	0.000876	CcSEcCtD
Topiramate—Myalgia—Carmustine—lymphatic system cancer	0.000876	0.000876	CcSEcCtD
Topiramate—Anxiety—Carmustine—lymphatic system cancer	0.000873	0.000873	CcSEcCtD
Topiramate—Paraesthesia—Bleomycin—lymphatic system cancer	0.000864	0.000864	CcSEcCtD
Topiramate—Malaise—Mitoxantrone—lymphatic system cancer	0.000863	0.000863	CcSEcCtD
Topiramate—Dyspnoea—Bleomycin—lymphatic system cancer	0.000858	0.000858	CcSEcCtD
Topiramate—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000856	0.000856	CcSEcCtD
Topiramate—Convulsion—Vincristine—lymphatic system cancer	0.000851	0.000851	CcSEcCtD
Topiramate—Hypertension—Vincristine—lymphatic system cancer	0.000848	0.000848	CcSEcCtD
Topiramate—Confusional state—Carmustine—lymphatic system cancer	0.000847	0.000847	CcSEcCtD
Topiramate—Oedema—Carmustine—lymphatic system cancer	0.00084	0.00084	CcSEcCtD
Topiramate—Decreased appetite—Bleomycin—lymphatic system cancer	0.000836	0.000836	CcSEcCtD
Topiramate—Myalgia—Vincristine—lymphatic system cancer	0.000836	0.000836	CcSEcCtD
Topiramate—Visual disturbance—Methotrexate—lymphatic system cancer	0.000835	0.000835	CcSEcCtD
Topiramate—Cough—Mitoxantrone—lymphatic system cancer	0.000835	0.000835	CcSEcCtD
Topiramate—Infection—Carmustine—lymphatic system cancer	0.000834	0.000834	CcSEcCtD
Topiramate—Vomiting—Fludarabine—lymphatic system cancer	0.000834	0.000834	CcSEcCtD
Topiramate—Convulsion—Mitoxantrone—lymphatic system cancer	0.000829	0.000829	CcSEcCtD
Topiramate—Rash—Fludarabine—lymphatic system cancer	0.000828	0.000828	CcSEcCtD
Topiramate—Dermatitis—Fludarabine—lymphatic system cancer	0.000827	0.000827	CcSEcCtD
Topiramate—Hypertension—Mitoxantrone—lymphatic system cancer	0.000826	0.000826	CcSEcCtD
Topiramate—Pain—Bleomycin—lymphatic system cancer	0.000823	0.000823	CcSEcCtD
Topiramate—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000822	0.000822	CcSEcCtD
Topiramate—Headache—Fludarabine—lymphatic system cancer	0.000822	0.000822	CcSEcCtD
Topiramate—Tachycardia—Carmustine—lymphatic system cancer	0.00082	0.00082	CcSEcCtD
Topiramate—Chest pain—Mitoxantrone—lymphatic system cancer	0.000815	0.000815	CcSEcCtD
Topiramate—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000815	0.000815	CcSEcCtD
Topiramate—Myalgia—Mitoxantrone—lymphatic system cancer	0.000815	0.000815	CcSEcCtD
Topiramate—Anxiety—Mitoxantrone—lymphatic system cancer	0.000812	0.000812	CcSEcCtD
Topiramate—Lethargy—Methotrexate—lymphatic system cancer	0.000808	0.000808	CcSEcCtD
Topiramate—Discomfort—Mitoxantrone—lymphatic system cancer	0.000805	0.000805	CcSEcCtD
Topiramate—Oedema—Vincristine—lymphatic system cancer	0.000802	0.000802	CcSEcCtD
Topiramate—Anorexia—Carmustine—lymphatic system cancer	0.000801	0.000801	CcSEcCtD
Topiramate—Infection—Vincristine—lymphatic system cancer	0.000797	0.000797	CcSEcCtD
Topiramate—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000793	0.000793	CcSEcCtD
Topiramate—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000792	0.000792	CcSEcCtD
Topiramate—Confusional state—Mitoxantrone—lymphatic system cancer	0.000787	0.000787	CcSEcCtD
Topiramate—Nervous system disorder—Vincristine—lymphatic system cancer	0.000786	0.000786	CcSEcCtD
Topiramate—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000785	0.000785	CcSEcCtD
Topiramate—Hypotension—Carmustine—lymphatic system cancer	0.000785	0.000785	CcSEcCtD
Topiramate—Oedema—Mitoxantrone—lymphatic system cancer	0.000781	0.000781	CcSEcCtD
Topiramate—Nausea—Fludarabine—lymphatic system cancer	0.00078	0.00078	CcSEcCtD
Topiramate—Infection—Mitoxantrone—lymphatic system cancer	0.000776	0.000776	CcSEcCtD
Topiramate—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000775	0.000775	CcSEcCtD
Topiramate—Shock—Mitoxantrone—lymphatic system cancer	0.000768	0.000768	CcSEcCtD
Topiramate—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000765	0.000765	CcSEcCtD
Topiramate—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000765	0.000765	CcSEcCtD
Topiramate—Urticaria—Bleomycin—lymphatic system cancer	0.000764	0.000764	CcSEcCtD
Topiramate—Anorexia—Vincristine—lymphatic system cancer	0.000764	0.000764	CcSEcCtD
Topiramate—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000762	0.000762	CcSEcCtD
Topiramate—Body temperature increased—Bleomycin—lymphatic system cancer	0.000761	0.000761	CcSEcCtD
Topiramate—Insomnia—Carmustine—lymphatic system cancer	0.00076	0.00076	CcSEcCtD
Topiramate—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000758	0.000758	CcSEcCtD
Topiramate—Irritability—Methotrexate—lymphatic system cancer	0.000756	0.000756	CcSEcCtD
Topiramate—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000755	0.000755	CcSEcCtD
Topiramate—Paraesthesia—Carmustine—lymphatic system cancer	0.000754	0.000754	CcSEcCtD
Topiramate—Mood swings—Methotrexate—lymphatic system cancer	0.00075	0.00075	CcSEcCtD
Topiramate—Hypotension—Vincristine—lymphatic system cancer	0.000749	0.000749	CcSEcCtD
Topiramate—Dyspnoea—Carmustine—lymphatic system cancer	0.000749	0.000749	CcSEcCtD
Topiramate—Somnolence—Carmustine—lymphatic system cancer	0.000747	0.000747	CcSEcCtD
Topiramate—Anorexia—Mitoxantrone—lymphatic system cancer	0.000744	0.000744	CcSEcCtD
Topiramate—Ataxia—Methotrexate—lymphatic system cancer	0.000744	0.000744	CcSEcCtD
Topiramate—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.000731	0.000731	CcSEcCtD
Topiramate—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000731	0.000731	CcSEcCtD
Topiramate—Decreased appetite—Carmustine—lymphatic system cancer	0.00073	0.00073	CcSEcCtD
Topiramate—Hypotension—Mitoxantrone—lymphatic system cancer	0.00073	0.00073	CcSEcCtD
Topiramate—Insomnia—Vincristine—lymphatic system cancer	0.000725	0.000725	CcSEcCtD
Topiramate—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000725	0.000725	CcSEcCtD
Topiramate—Paraesthesia—Vincristine—lymphatic system cancer	0.00072	0.00072	CcSEcCtD
Topiramate—Pain—Carmustine—lymphatic system cancer	0.000718	0.000718	CcSEcCtD
Topiramate—Constipation—Carmustine—lymphatic system cancer	0.000718	0.000718	CcSEcCtD
Topiramate—Breast disorder—Methotrexate—lymphatic system cancer	0.000715	0.000715	CcSEcCtD
Topiramate—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.000713	0.000713	CcSEcCtD
Topiramate—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000711	0.000711	CcSEcCtD
Topiramate—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000709	0.000709	CcSEcCtD
Topiramate—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000701	0.000701	CcSEcCtD
Topiramate—Decreased appetite—Vincristine—lymphatic system cancer	0.000697	0.000697	CcSEcCtD
Topiramate—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000696	0.000696	CcSEcCtD
Topiramate—Somnolence—Mitoxantrone—lymphatic system cancer	0.000694	0.000694	CcSEcCtD
Topiramate—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000692	0.000692	CcSEcCtD
Topiramate—Feeling abnormal—Carmustine—lymphatic system cancer	0.000692	0.000692	CcSEcCtD
Topiramate—Fatigue—Vincristine—lymphatic system cancer	0.000691	0.000691	CcSEcCtD
Topiramate—Asthenia—Bleomycin—lymphatic system cancer	0.00069	0.00069	CcSEcCtD
Topiramate—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000687	0.000687	CcSEcCtD
Topiramate—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000687	0.000687	CcSEcCtD
Topiramate—Constipation—Vincristine—lymphatic system cancer	0.000686	0.000686	CcSEcCtD
Topiramate—Pain—Vincristine—lymphatic system cancer	0.000686	0.000686	CcSEcCtD
Topiramate—Asthma—Methotrexate—lymphatic system cancer	0.000684	0.000684	CcSEcCtD
Topiramate—Pruritus—Bleomycin—lymphatic system cancer	0.000681	0.000681	CcSEcCtD
Topiramate—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000679	0.000679	CcSEcCtD
Topiramate—Eosinophilia—Methotrexate—lymphatic system cancer	0.000677	0.000677	CcSEcCtD
Topiramate—Fatigue—Mitoxantrone—lymphatic system cancer	0.000673	0.000673	CcSEcCtD
Topiramate—Pancreatitis—Methotrexate—lymphatic system cancer	0.000671	0.000671	CcSEcCtD
Topiramate—Constipation—Mitoxantrone—lymphatic system cancer	0.000668	0.000668	CcSEcCtD
Topiramate—Pain—Mitoxantrone—lymphatic system cancer	0.000668	0.000668	CcSEcCtD
Topiramate—Abdominal pain—Carmustine—lymphatic system cancer	0.000664	0.000664	CcSEcCtD
Topiramate—Body temperature increased—Carmustine—lymphatic system cancer	0.000664	0.000664	CcSEcCtD
Topiramate—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.000656	0.000656	CcSEcCtD
Topiramate—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000656	0.000656	CcSEcCtD
Topiramate—Pancytopenia—Methotrexate—lymphatic system cancer	0.00065	0.00065	CcSEcCtD
Topiramate—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000643	0.000643	CcSEcCtD
Topiramate—Dysuria—Methotrexate—lymphatic system cancer	0.00064	0.00064	CcSEcCtD
Topiramate—Neutropenia—Methotrexate—lymphatic system cancer	0.00064	0.00064	CcSEcCtD
Topiramate—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000639	0.000639	CcSEcCtD
Topiramate—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000636	0.000636	CcSEcCtD
Topiramate—Abdominal pain—Vincristine—lymphatic system cancer	0.000634	0.000634	CcSEcCtD
Topiramate—Body temperature increased—Vincristine—lymphatic system cancer	0.000634	0.000634	CcSEcCtD
Topiramate—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.00063	0.00063	CcSEcCtD
Topiramate—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000624	0.000624	CcSEcCtD
Topiramate—Urticaria—Mitoxantrone—lymphatic system cancer	0.00062	0.00062	CcSEcCtD
Topiramate—Hypersensitivity—Carmustine—lymphatic system cancer	0.000619	0.000619	CcSEcCtD
Topiramate—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000617	0.000617	CcSEcCtD
Topiramate—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000617	0.000617	CcSEcCtD
Topiramate—Pneumonia—Methotrexate—lymphatic system cancer	0.000614	0.000614	CcSEcCtD
Topiramate—Vomiting—Bleomycin—lymphatic system cancer	0.000612	0.000612	CcSEcCtD
Topiramate—Infestation NOS—Methotrexate—lymphatic system cancer	0.00061	0.00061	CcSEcCtD
Topiramate—Infestation—Methotrexate—lymphatic system cancer	0.00061	0.00061	CcSEcCtD
Topiramate—Depression—Methotrexate—lymphatic system cancer	0.000608	0.000608	CcSEcCtD
Topiramate—Rash—Bleomycin—lymphatic system cancer	0.000607	0.000607	CcSEcCtD
Topiramate—Dermatitis—Bleomycin—lymphatic system cancer	0.000606	0.000606	CcSEcCtD
Topiramate—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000605	0.000605	CcSEcCtD
Topiramate—Asthenia—Carmustine—lymphatic system cancer	0.000603	0.000603	CcSEcCtD
Topiramate—Renal failure—Methotrexate—lymphatic system cancer	0.0006	0.0006	CcSEcCtD
Topiramate—Stomatitis—Methotrexate—lymphatic system cancer	0.000595	0.000595	CcSEcCtD
Topiramate—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000593	0.000593	CcSEcCtD
Topiramate—Hypersensitivity—Vincristine—lymphatic system cancer	0.000591	0.000591	CcSEcCtD
Topiramate—Haematuria—Methotrexate—lymphatic system cancer	0.000582	0.000582	CcSEcCtD
Topiramate—Epistaxis—Methotrexate—lymphatic system cancer	0.000575	0.000575	CcSEcCtD
Topiramate—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000575	0.000575	CcSEcCtD
Topiramate—Asthenia—Vincristine—lymphatic system cancer	0.000575	0.000575	CcSEcCtD
Topiramate—Diarrhoea—Carmustine—lymphatic system cancer	0.000575	0.000575	CcSEcCtD
Topiramate—Nausea—Bleomycin—lymphatic system cancer	0.000572	0.000572	CcSEcCtD
Topiramate—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000569	0.000569	CcSEcCtD
Topiramate—Asthenia—Mitoxantrone—lymphatic system cancer	0.00056	0.00056	CcSEcCtD
Topiramate—Dizziness—Carmustine—lymphatic system cancer	0.000555	0.000555	CcSEcCtD
Topiramate—Haemoglobin—Methotrexate—lymphatic system cancer	0.00055	0.00055	CcSEcCtD
Topiramate—Diarrhoea—Vincristine—lymphatic system cancer	0.000549	0.000549	CcSEcCtD
Topiramate—Hepatitis—Methotrexate—lymphatic system cancer	0.000548	0.000548	CcSEcCtD
Topiramate—Haemorrhage—Methotrexate—lymphatic system cancer	0.000548	0.000548	CcSEcCtD
Topiramate—Pharyngitis—Methotrexate—lymphatic system cancer	0.000544	0.000544	CcSEcCtD
Topiramate—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000541	0.000541	CcSEcCtD
Topiramate—Urethral disorder—Methotrexate—lymphatic system cancer	0.000537	0.000537	CcSEcCtD
Topiramate—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000534	0.000534	CcSEcCtD
Topiramate—Vomiting—Carmustine—lymphatic system cancer	0.000534	0.000534	CcSEcCtD
Topiramate—Dizziness—Vincristine—lymphatic system cancer	0.00053	0.00053	CcSEcCtD
Topiramate—Rash—Carmustine—lymphatic system cancer	0.00053	0.00053	CcSEcCtD
Topiramate—Dermatitis—Carmustine—lymphatic system cancer	0.000529	0.000529	CcSEcCtD
Topiramate—Visual impairment—Methotrexate—lymphatic system cancer	0.000528	0.000528	CcSEcCtD
Topiramate—Headache—Carmustine—lymphatic system cancer	0.000526	0.000526	CcSEcCtD
Topiramate—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000518	0.000518	CcSEcCtD
Topiramate—Eye disorder—Methotrexate—lymphatic system cancer	0.000512	0.000512	CcSEcCtD
Topiramate—Tinnitus—Methotrexate—lymphatic system cancer	0.000511	0.000511	CcSEcCtD
Topiramate—Vomiting—Vincristine—lymphatic system cancer	0.00051	0.00051	CcSEcCtD
Topiramate—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000508	0.000508	CcSEcCtD
Topiramate—Rash—Vincristine—lymphatic system cancer	0.000506	0.000506	CcSEcCtD
Topiramate—Dermatitis—Vincristine—lymphatic system cancer	0.000505	0.000505	CcSEcCtD
Topiramate—Headache—Vincristine—lymphatic system cancer	0.000502	0.000502	CcSEcCtD
Topiramate—Nausea—Carmustine—lymphatic system cancer	0.000499	0.000499	CcSEcCtD
Topiramate—Angiopathy—Methotrexate—lymphatic system cancer	0.000497	0.000497	CcSEcCtD
Topiramate—Vomiting—Mitoxantrone—lymphatic system cancer	0.000496	0.000496	CcSEcCtD
Topiramate—Immune system disorder—Methotrexate—lymphatic system cancer	0.000495	0.000495	CcSEcCtD
Topiramate—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000494	0.000494	CcSEcCtD
Topiramate—Rash—Mitoxantrone—lymphatic system cancer	0.000492	0.000492	CcSEcCtD
Topiramate—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000492	0.000492	CcSEcCtD
Topiramate—Chills—Methotrexate—lymphatic system cancer	0.000491	0.000491	CcSEcCtD
Topiramate—Headache—Mitoxantrone—lymphatic system cancer	0.000489	0.000489	CcSEcCtD
Topiramate—Alopecia—Methotrexate—lymphatic system cancer	0.000484	0.000484	CcSEcCtD
Topiramate—Mental disorder—Methotrexate—lymphatic system cancer	0.00048	0.00048	CcSEcCtD
Topiramate—Malnutrition—Methotrexate—lymphatic system cancer	0.000477	0.000477	CcSEcCtD
Topiramate—Erythema—Methotrexate—lymphatic system cancer	0.000477	0.000477	CcSEcCtD
Topiramate—Nausea—Vincristine—lymphatic system cancer	0.000476	0.000476	CcSEcCtD
Topiramate—Dysgeusia—Methotrexate—lymphatic system cancer	0.000467	0.000467	CcSEcCtD
Topiramate—Nausea—Mitoxantrone—lymphatic system cancer	0.000464	0.000464	CcSEcCtD
Topiramate—Back pain—Methotrexate—lymphatic system cancer	0.000461	0.000461	CcSEcCtD
Topiramate—Vision blurred—Methotrexate—lymphatic system cancer	0.000449	0.000449	CcSEcCtD
Topiramate—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000442	0.000442	CcSEcCtD
Topiramate—Anaemia—Methotrexate—lymphatic system cancer	0.000441	0.000441	CcSEcCtD
Topiramate—Malaise—Methotrexate—lymphatic system cancer	0.00043	0.00043	CcSEcCtD
Topiramate—Vertigo—Methotrexate—lymphatic system cancer	0.000428	0.000428	CcSEcCtD
Topiramate—Leukopenia—Methotrexate—lymphatic system cancer	0.000427	0.000427	CcSEcCtD
Topiramate—Cough—Methotrexate—lymphatic system cancer	0.000416	0.000416	CcSEcCtD
Topiramate—Convulsion—Methotrexate—lymphatic system cancer	0.000413	0.000413	CcSEcCtD
Topiramate—Chest pain—Methotrexate—lymphatic system cancer	0.000406	0.000406	CcSEcCtD
Topiramate—Arthralgia—Methotrexate—lymphatic system cancer	0.000406	0.000406	CcSEcCtD
Topiramate—Myalgia—Methotrexate—lymphatic system cancer	0.000406	0.000406	CcSEcCtD
Topiramate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000403	0.000403	CcSEcCtD
Topiramate—Discomfort—Methotrexate—lymphatic system cancer	0.000401	0.000401	CcSEcCtD
Topiramate—Confusional state—Methotrexate—lymphatic system cancer	0.000392	0.000392	CcSEcCtD
Topiramate—Infection—Methotrexate—lymphatic system cancer	0.000387	0.000387	CcSEcCtD
Topiramate—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000382	0.000382	CcSEcCtD
Topiramate—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000381	0.000381	CcSEcCtD
Topiramate—Skin disorder—Methotrexate—lymphatic system cancer	0.000378	0.000378	CcSEcCtD
Topiramate—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000376	0.000376	CcSEcCtD
Topiramate—Anorexia—Methotrexate—lymphatic system cancer	0.000371	0.000371	CcSEcCtD
Topiramate—Hypotension—Methotrexate—lymphatic system cancer	0.000364	0.000364	CcSEcCtD
Topiramate—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000354	0.000354	CcSEcCtD
Topiramate—Insomnia—Methotrexate—lymphatic system cancer	0.000352	0.000352	CcSEcCtD
Topiramate—Paraesthesia—Methotrexate—lymphatic system cancer	0.000349	0.000349	CcSEcCtD
Topiramate—Dyspnoea—Methotrexate—lymphatic system cancer	0.000347	0.000347	CcSEcCtD
Topiramate—Somnolence—Methotrexate—lymphatic system cancer	0.000346	0.000346	CcSEcCtD
Topiramate—Dyspepsia—Methotrexate—lymphatic system cancer	0.000342	0.000342	CcSEcCtD
Topiramate—Decreased appetite—Methotrexate—lymphatic system cancer	0.000338	0.000338	CcSEcCtD
Topiramate—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000336	0.000336	CcSEcCtD
Topiramate—Fatigue—Methotrexate—lymphatic system cancer	0.000335	0.000335	CcSEcCtD
Topiramate—Pain—Methotrexate—lymphatic system cancer	0.000333	0.000333	CcSEcCtD
Topiramate—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000321	0.000321	CcSEcCtD
Topiramate—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000318	0.000318	CcSEcCtD
Topiramate—Urticaria—Methotrexate—lymphatic system cancer	0.000309	0.000309	CcSEcCtD
Topiramate—Abdominal pain—Methotrexate—lymphatic system cancer	0.000308	0.000308	CcSEcCtD
Topiramate—Body temperature increased—Methotrexate—lymphatic system cancer	0.000308	0.000308	CcSEcCtD
Topiramate—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000287	0.000287	CcSEcCtD
Topiramate—Asthenia—Methotrexate—lymphatic system cancer	0.000279	0.000279	CcSEcCtD
Topiramate—Pruritus—Methotrexate—lymphatic system cancer	0.000275	0.000275	CcSEcCtD
Topiramate—Diarrhoea—Methotrexate—lymphatic system cancer	0.000266	0.000266	CcSEcCtD
Topiramate—Dizziness—Methotrexate—lymphatic system cancer	0.000257	0.000257	CcSEcCtD
Topiramate—Vomiting—Methotrexate—lymphatic system cancer	0.000247	0.000247	CcSEcCtD
Topiramate—Rash—Methotrexate—lymphatic system cancer	0.000245	0.000245	CcSEcCtD
Topiramate—Dermatitis—Methotrexate—lymphatic system cancer	0.000245	0.000245	CcSEcCtD
Topiramate—Headache—Methotrexate—lymphatic system cancer	0.000244	0.000244	CcSEcCtD
Topiramate—Nausea—Methotrexate—lymphatic system cancer	0.000231	0.000231	CcSEcCtD
